Mr Harsh Nijhawan
Higher Degree by Research Candidate
School of Pharmacy and Biomedical Sciences
College of Health
| Date | Institution name | Country | Title |
|---|---|---|---|
| NMIMS University, Mumbai, India | India | M. Pharm + M.B.A | |
| University of Mumbai | India | B. Pharm |
| Year | Citation |
|---|---|
| 2026 | Singhal, D., Nijhawan, H. P., & Yadav, K. S. (2026). Enhanced Ocular Delivery of Bimatoprost Using Surfactant and Lipid-Based Bilosomes in Situ Gel in Rabbits and Glaucoma-Induced Wistar Rats. Bionanoscience, 16(1). Scopus2 |
| 2026 | Chhabada, Y., Nijhawan, H. P., & Yadav, K. S. (2026). Microneedle-Based Transdermal Delivery for Parkinson’s Disease: A Paradigm Shift in Patient-Centric Therapy. BioNanoScience, 16(6), 363-1-363 -19. |
| 2026 | Nijhawan, H. P., Vyas, J., Verma, P., & Yadav, K. S. (2026). Hyaluronic acid-coated cubosomal in situ gel for Brimonidine Tartrate: a sustained delivery system with enhanced ocular bioavailability and intraocular pressure reduction. Journal of Biomaterials Science Polymer Edition, 37(6), 1119-1152. Scopus8 WoS9 |
| 2026 | Rajbhar, N., Nijhawan, H. P., & Yadav, K. S. (2026). Bilayered dissolving microneedles for microemulsion-mediated ocular delivery of brimonidine tartrate in glaucoma therapy. Journal of Biomaterials Science Polymer Edition, 42 pages. Scopus1 WoS1 |
| 2026 | Jain, A., Nijhawan, H. P., & Yadav, K. S. (2026). DoE-Optimized Chitosan-Coated pH-Sensitive Liposomes for Targeted Nose-to-Brain Delivery of Temozolomide. AAPS Pharmscitech, 27(3), 33 pages. |
| 2025 | Yadav, K. S., Nijhawan, H. P., Nirale, P., Singhal, D., & Soni, G. (2025). Efficient nose-to-brain delivery of chitosan-coated resveratrol nanoemulsion in rats: Formulation optimized using D-optimal mixture design. Journal of Dispersion Science and Technology, 15 pages. Scopus14 WoS13 |
| 2025 | Deshmukh, S. S., Nijhawan, H. P., & Yadav, K. S. (2025). Chitosan-based copolymeric nanocarrier systems: A novel paradigm for targeted breast cancer therapy. International Journal of Biological Macromolecules, 319(Pt 3), 13 pages. Scopus12 WoS11 Europe PMC2 |
| 2025 | Rajbhar, N., Singhal, D., Nijhawan, H. P., Verma, P., Soni, G., & Yadav, K. S. (2025). Bilosomes as a novel ocular drug delivery system: Assessing the material attributes, process parameters, and quality attributes. Experimental Eye Research, 255, 13 pages. Scopus15 WoS15 Europe PMC5 |
| 2025 | Singh, R., Nijhawan, H. P., & Yadav, K. S. (2025). Breaking the Barrier: Enhanced Transdermal Benztropine Delivery Using Nanoparticle-loaded Dissolving Microneedles. Bionanoscience, 15(3), 21 pages. Scopus8 WoS8 |
| 2024 | Nijhawan, H. P., Prabhakar, B., & Yadav, K. S. (2024). Central composite design augmented quality-by-design-based systematic formulation of erlotinib hydrochloride-loaded chitosan-poly (lactic-co-glycolic acid) nanoparticles. Therapeutic Delivery, 15(6), 427-447. Scopus20 WoS18 Europe PMC5 |
| 2024 | Nijhawan, H. P., Shyamsundar, P., Prabhakar, B., & Yadav, K. S. (2024). PEGylated pH-Responsive Liposomes for Enhancing the Intracellular Uptake and Cytotoxicity of Paclitaxel in MCF-7 Breast Cancer Cells. AAPS Pharmscitech, 25(7), 16 pages. Scopus25 WoS23 Europe PMC9 |
| 2024 | Yadav, K. S., Nijhawan, H. P., Gite, P., & Shetty, S. (2024). Nanofiber power: Reinforcing in-situ hydrogel for enhanced rivastigmine delivery. Journal of Drug Delivery Science and Technology, 101, 15 pages. Scopus13 WoS13 |
| 2023 | Nijhawan, H. P., Prabhakar, B., Misra, A., & Yadav, K. S. (2023). Fragmented antibodies in non-small cell lung cancer: A novel nano-engineered delivery system for detection and treatment of cancer. Drug Discovery Today, 28(11), 9 pages. Scopus18 WoS18 Europe PMC8 |
| 2023 | Bhargave, H., Nijhawan, H., & Yadav, K. S. (2023). PEGylated Erlotinib HCl Injectable Nanoformulation for Improved Bioavailability. AAPS Pharmscitech, 24(4), 15 pages. Scopus24 WoS24 Europe PMC10 |
| 2023 | Yadav, K. S., Raut, H. C., & Nijhawan, H. P. (2023). Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells. Pharmaceutical Development and Technology, 28(8), 755-767. Scopus17 WoS19 Europe PMC7 |
| 2022 | Raut, H., Jadhav, C., Shetty, K., Laxane, N., Nijhawan, H. P., Rao, G. K., . . . Yadav, K. S. (2022). Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications. Opennano, 8, 100103. Scopus31 |
| Year | Citation |
|---|---|
| 2024 | Yasaswi, P. S., Nijhawan, H. P., Prabhakar, B., Dutt, S., & Yadav, K. S. (2024). Emerging drug delivery systems to alter tumor immunosuppressive microenvironment: Overcoming the challenges in immunotherapy for glioblastoma. In D. Teplow (Ed.), CANCER IMMUNOTHERAPY (Vol. 209, pp. 165-182). ELSEVIER ACADEMIC PRESS INC. DOI Scopus15 WoS15 Europe PMC4 |
Connect With Me
External Profiles
